Comparison Chart TScan Therapeutics, Inc.

Stocks

TCRX

US89854M1018

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-08-03 EDT			5-day change	1st Jan Change
0.7234 ^USD	-2.64%		-5.84%	-27.66%

07-29	Tscan Therapeutics Doses First Patient in Phase 3 ALLOHA-2 Trial Evaluating TSC-101 in Patients with Heme Malignancies	CI
06-22	TScan Therapeutics Presents Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Compared values

		Sector	Change	5-day change	YTD change	1-year change	5-year change	Capi.	ST	MT	LT
	TSCAN THERAPEUTICS, INC.	Bio Therapeutic Drugs	-2.64%	-5.84%	-27.66%	-55.35%	-93.34%	47.27M